Navigation Links
Regenicin COO Receives Citizenship Award from VFW Post 1 in Colorado

LITTLE FALLS, N.J., Jan. 6, 2011 /PRNewswire/ -- Regenicin's (OTC Bulletin Board: RGIN) Chief Operating Officer, Chris Hadsall, recently received the 2010 Citizenship Award for his volunteer work with the VET Foundation and disabled veterans. Mr. Hadsall received the award at the VFW's 111th Annual Founders Day Banquet in December.  Hadsall joins a long list of notable citizens and groups bettering the lives of Veterans in the Colorado community. 

Mr. Hadsall served our country as a decorated Operations and Intelligence Officer for the U.S. Marine Corps, where his responsibilities included supervision of operations, logistics and communications for over 150 marines. During his career in the USMC, Mr. Hadsall helped establish the Wounded Warrior Program, which provides unique services to wounded servicemen and founded the VET Foundation, an organization committed to helping service disabled veterans transition out of the military.  As a wounded veteran himself, Mr. Hadsall has been awarded the Purple Heart as well as the Iraqi Freedom Medal for his service to our country.  

"We congratulate Chris on his VFW Citizenship Award for his volunteer work with the Vet Foundation," says Randall McCoy, CEO of Regenicin. "We are honored and proud to have such an experienced, well respected citizen and former Marine heading up the operations for Regenicin."

About Regenicin

Regenicin, Inc., (OTC Bulletin Board: RGIN) is a biotechnology company specializing in the development and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world-class team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. Regenicin is playing a critical role in the development of the therapeutic candidate, PermaDerm™, an exciting breakthrough technology that uses the patient's own skin cells to generate living, tissue-engineered skin for the treatment of chronic burns.  The company is publicly traded with headquarters in Little Falls, NJ. Additional information can be found in the company's filings with the Securities and Exchange Commission located at

Safe Harbor Statement.  This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition.  A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission.  The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Regenicin(TM), Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Regenicin Announces Closing of Private Placement Transaction
2. Regenicin Changes Its Ticker Symbol to RGIN.OB
3. Regenicin Presentation Now Available Online at
4. Regenicin to Present at Event Celebrating Advancements in Regenerative Medicine
5. Regenicin to Present Live at on November 4th
6. Regenicin Appoints Renowned New York Dermatologist, Dr. Gervaise Gerstner to Scientific Advisory Board
7. Regenicin to Form Scientific Advisory Board
8. Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer
9. Former Fujifilm Medical Systems USA Executive John J. Weber Agrees to Join Regenicin™ as a Member of Its Board of Directors and Interim CFO
10. Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville
11. Foundation Venture Capital Group Company Receives $8.2 Million DoD Contract
Post Your Comments:
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology:
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/12/2016)... , May 12, 2016 ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):